Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT6A | Q92794 | 6/20 | 0.38 |
| ▸ | GBA1 | P04062 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.35 |
| ▸ | FEN1 | P39748 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3177510 | 0.99 | KAT6A (0.37) | KAT6AGBA1ALDH1A1TSHRCNR2 | |
| SCHEMBL3185411 | 0.87 | GBA1 (0.41) | KAT6AGBA1ALDH1A1TSHRCNR2 | |
| SCHEMBL3201091 | 0.84 | GBA1 (0.36) | KAT6AGBA1ALDH1A1TSHRCNR2 | |
| SCHEMBL3189775 | 0.82 | GBA1 (0.38) | KAT6AGBA1ALDH1A1TSHRCNR2 | |
| SCHEMBL3197766 | 0.81 | MMP1 (0.41) | ALDH1A1MEN1KMT2A | |
| SCHEMBL3196911 | 0.81 | MMP1 (0.40) | ALDH1A1MEN1KMT2A | |
| SCHEMBL3199408 | 0.80 | GBA1 (0.40) | KAT6AGBA1ALDH1A1TSHRCNR2 | |
| SCHEMBL3189173 | 0.79 | MMP1 (0.40) | ALDH1A1MEN1KMT2AATM | |
| SCHEMBL3189848 | 0.79 | GBA1 (0.39) | KAT6AGBA1ALDH1A1TSHRCNR2 | |
| SCHEMBL3194908 | 0.78 | ALDH1A1 (0.39) | KAT6AGBA1ALDH1A1TSHRCNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100120725-A1 | Substituted Phenylsulfonamide Inhibitors of Beta Amyloid Production | WYETH LLC (US) | 2010-05-13 | — | — | US | claimed |
| US-7671075-B2 | Substituted phenylsulfonamide inhibitors of beta amyloid production | WYETH (US) | 2010-03-02 | — | — | US | claimed |
| US-20070037778-A1 | Therapy and prophylaxis of Alzheimer's Disease and Down's syndrome; inhibiting beta amyloid production; 2,4-difluoro-N-[(1S,2S)-1-(hydroxymethyl)-2-methylbutyl]benzenesulfonamide | WYETH (US) | 2007-02-15 | — | — | US | claimed |
| US-7166622-B2 | Substituted phenylsulfonamide inhibitors of beta amyloid production | WYETH (US) | 2007-01-23 | — | — | US | claimed |
| US-20100120725-A1 | Substituted Phenylsulfonamide Inhibitors of Beta Amyloid Production | WYETH LLC (US) | 2010-05-13 | — | — | US | disclosed |
| US-7671075-B2 | Substituted phenylsulfonamide inhibitors of beta amyloid production | WYETH (US) | 2010-03-02 | — | — | US | disclosed |
| EP-1549306-A4 | SUBSTITUTED PHENYLSULFONAMIDE INHIBITORS OF BETA AMYLOID PRODUCTION | WYETH CORP (US) | 2007-06-06 | — | — | EP | disclosed |
| US-20070037778-A1 | Therapy and prophylaxis of Alzheimer's Disease and Down's syndrome; inhibiting beta amyloid production; 2,4-difluoro-N-[(1S,2S)-1-(hydroxymethyl)-2-methylbutyl]benzenesulfonamide | WYETH (US) | 2007-02-15 | — | — | US | disclosed |
| US-7166622-B2 | Substituted phenylsulfonamide inhibitors of beta amyloid production | WYETH (US) | 2007-01-23 | — | — | US | disclosed |
| EP-1549306-A1 | SUBSTITUTED PHENYLSULFONAMIDE INHIBITORS OF BETA AMYLOID PRODUCTION | Wyeth (US) | 2005-07-06 | — | — | EP | disclosed |
| US-20040006050-A1 | Substituted phenylsulfonamide inhibitors of beta amyloid production | WYETH (US) | 2004-01-08 | — | — | US | disclosed |
| WO-2003103660-A1 | SUBSTITUTED PHENYLSULFONAMIDE INHIBITORS OF BETA AMYLOID PRODUCTION | WYETH (US) | 2003-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120725-A1 | Substituted Phenylsulfonamide Inhibitors of Beta Amyloid Production | APP, BACE1, PSEN1 | KAT6A 3869/4885GBA1 140/4885ALDH1A1 1743/4885 |
| US-20070037778-A1 | Therapy and prophylaxis of Alzheimer's Disease and Down's syndrome; inhibiting beta amyloid production; 2,4-difluoro-N-[(1S,2S)-1-(hydroxymethyl)-2-methylbutyl]benzenesulfonamide | BACE1, APP, PSEN1 | KAT6A 3635/4885GBA1 282/4885ALDH1A1 1013/4885 |
| US-20040006050-A1 | Substituted phenylsulfonamide inhibitors of beta amyloid production | APP, BACE1, PSEN1 | KAT6A 3798/4885GBA1 114/4885ALDH1A1 902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.